Abstract
In the present study, we examined the effects of dopamine (DA) receptor antagonists infused into the nucleus accumbens septi (NAS) on analgesia induced by intra-ventral tegmental area (VTA) infusions of the substance P (SP) analog, DiMe-C7 or morphine and intra-NAS infusions of amphetamine. Rats received intra-NAS infusions of either the mixed DA receptor antagonist flupenthixol (1.5 or 3.0 μg/0.5 μl/side; DiMe-C7 only), the DA D1/D5 receptor antagonist SCH 23390 (0.1 μg/0.5 μl/side; DiMe-C7 only) or the DA D2-type receptor antagonist raclopride (1.0, 3.0 or 5.0 μg/0.5 μl/side). Ten minutes later, rats received intra-VTA infusions of DiMe-C7 (3.0 μg/0.5 μl/side) or morphine (3.0 μg/0.5 μl/side) or intra-NAS infusions of amphetamine (2.5 μg/0.5 μl/side). Animals were then administered the formalin test for tonic pain. Intra-NAS raclopride prevented analgesia induced by intra-VTA DiMe-C7, intra-VTA morphine and intra-NAS amphetamine. Similarly, intra-NAS flupenthixol or SCH 23390 attenuated the analgesia induced by intra-VTA DiMe-C7. These findings suggest that tonic pain is inhibited, at least in part, by enhanced DA released from terminals of mesolimbic neurons. Furthermore, the evidence that SP and opioids in the VTA mediate stress-induced analgesia suggests that the pain-suppression system involving the activation of mesolimbic DA neurons is naturally triggered by exposure to stress, pain or both.
Footnotes
-
Send reprint requests to: Dr. Jane Stewart, Center for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, 1455 de Maisonneuve Blvd. West, Montréal, Québec, Canada, H3G 1M8.
-
↵1 This work was supported by grants from the Medical Research Council of Canada and Fonds pour la Formation de Chercheurs et l’Aide à la Recherche (Québec).
- Abbreviations:
- VTA
- ventral tegmental area
- DA
- dopamine
- NAS
- nucleus accumbens septi
- SP
- substance P
- 6-OHDA
- 6-hydroxydopamine
- ANOVA
- analysis of variance
- Received September 12, 1997.
- Accepted December 22, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|